Valneva Says Single-Dose Chikungunya Vaccine IXCHIQ Showed Antibody Persistence Consistent With Prior Results, In Line With Company Expectations, With 94% Seroresponse At Year 5 Across Age Groups
Benzinga Newsdesk 14 hours ago
News
94% of participants maintained seroresponse five years after a single vaccinationComparable antibody persistence observed in older (65+) and younger adultsData further reinforce IXCHIQ®'s differentiated profile with
- 94% of participants maintained seroresponse five years after a single vaccination
- Comparable antibody persistence observed in older (65+) and younger adults
- Data further reinforce IXCHIQ®'s differentiated profile with durable antibody persistence against an unpredictable outbreak disease